Summary

The value of drug treatment in angina pectoris can be accurately assessed by using reproducible treadmill exercise under controlled conditions. A "training" period to allow patients to become completely familiar with the test is of great importance, because during this period effort tolerance usually increases irrespective of drug therapy.

The change in effort tolerance after pronethalol or propranolol, compared with placebo, was measured in 20 patients. A wide variation in response was obtained, but the mean improvement of 36% was highly significant ($P < 0.001$).

We wish to thank Dr. G. W. Hayward for permission to study patients under his care, and also the Department of Medical Illustration for preparing the figure. Part of this work was carried out while one of us (D.A.B.) was in receipt of an Aylwen Bursary. Pronethalol and propranolol were supplied by the Pharmaceutical Division of Imperial Chemical Industries Ltd.

REFERENCES

- Abrahamsen, A. M., and Küll, F. (1966). *Brit. med. J.*, **1**, 456.
 Alleyne, G. A. O., Dickinson, C. J., Dornhorst, A. C., Fulton, R. M., Green, K. G., Hill, I. D., Hurst, P., Laurence, D. R., Pilkington, T., Prichard, B. N. C., Robinson, B., and Rosenheim, M. L. (1963). *Ibid.*, **2**, 1226.
 Apthorp, G. H., Chamberlain, D. A., and Hayward, G. W. (1964). *Brit. Heart J.*, **26**, 218.
 Birkett, D. A., Apthorp, G. H., Chamberlain, D. A., Hayward, G. W., and Tuckwell, E. G. (1965). *Brit. med. J.*, **2**, 187.
 Dornhorst, A. C., and Robinson, B. F. (1962). *Lancet*, **2**, 314.
 Hamer, J., Grandjean, T., Melendez, L., and Sowton, G. E. (1964). *Brit. med. J.*, **2**, 720.
 Keelan, P. J. R. B. (1965). *Ibid.*, **1**, 897.
 MacAlpin, R. N., Kattus, A. A., and Winfield, M. E. (1965). *Circulation*, **31**, 869.
 McNeill, R. S. (1964). *Lancet*, **2**, 1101.
 Muir, G. G., Chamberlain, D. A., and Tunstall Pedoc, D. (1964). *Ibid.*, **2**, 930.
 Paget, G. E. (1963). *Brit. med. J.*, **2**, 1266.
 Srivastava, S. C., Dewar, H. A., and Newell, D. J. (1964). *Ibid.*, **2**, 724.

Effect of Moderate Exercise on the Fibrinolytic System in Normal Young Men and Women

J. D. CASH,* M.B., B.SC., M.R.C.P.ED

Brit. med. J., 1966, **2**, 502-506

There is considerable evidence to show that exercise increases plasma fibrinolysis (Biggs *et al.*, 1947; Truelove, 1951; Fearnley and Lackner, 1955; Sherry *et al.*, 1959; Billimoria *et al.*, 1959; Ogston and Fullerton, 1961; Jang *et al.*, 1964; Ogston and McAndrew, 1964; Burt *et al.*, 1964) and that this is due to an increased level of plasminogen activator (Sawyer *et al.*, 1960; Iatridis and Ferguson, 1963). Careful analysis of the results of all these workers reveals that some of their subjects responded poorly. Those who have commented on these poor responders have given tentative explanations. Biggs *et al.* (1947) thought increased physical fitness relevant, Sawyer *et al.* (1960) inappropriate timing of sample collection, whereas Iatridis and Ferguson (1963) suggested that the reason might be the failure to show the usual reaction to stress or to the production of a fibrinolytic inhibitor. It is not possible to make any valid conclusions from these studies, however, because of the variation of fibrinolytic assays and in the type of exercise used in different laboratories. Of no less importance is the fact that in most studies exercise to exhaustion was used and therefore no attempt was made to examine individual reproducibility of response.

In view of Astrup's (1956) hypothesis that there exists a delicately balanced dynamic equilibrium between coagulation and fibrinolysis, and that disequilibrium might result in atherosclerosis and thrombus formation, then the concept of a poorly reactive fibrinolytic system in a small proportion of apparently healthy young persons would be of considerable interest.

This paper describes a series of experiments in which the fibrinolytic system was studied before and after a standard moderate exercise procedure in a group of young healthy subjects.

Subjects

The subjects were 25 healthy male and 25 healthy female volunteers aged 18 to 30 years. All subjects undertook the

exercise procedure on more than one occasion. Most experiments were repeated at weekly intervals, but a few at intervals of several months. Nine of the women, with a history of regular and trouble-free menstrual cycles, were studied at weekly intervals throughout a menstrual cycle.

Materials

Anticoagulant.—Sodium citrate B.P. 3.8%.

Buffers.—(a) Barbiturate buffer. Modified veronal buffer of pH 7.4 and ionic strength 0.15 (Owren, 1947). (b) Tris buffer. 0.15 M solution of tris—(hydroxymethyl)—amino-methane (Koch-Light Laboratories Ltd., batch No. 11342) adjusted to pH 7.8. (c) Phosphate buffer. 0.1 M at pH 7.6.

Fibrinogen.—A Blombäck and Blombäck (1957) preparation of human fibrinogen with a clottability of 97% (supplied by Kabi Pharmaceutical Company, batch No. 83164) was used. A 1.5 g./100 ml. solution of fibrinogen in tris buffer was stored in plastic tubes at -20°C . After thawing it was diluted to 0.15 g./100 ml. in tris buffer and used for fibrin plates.

Thrombin.—Topical thrombin (Parke Davis and Co., batch No. 03179A) was used. A solution of 50 units/ml. in tris buffer was prepared for fibrin plates, one of 5 units/ml. in barbiturate buffer for euglobulin lysis time estimations, and one of 100 units/ml. in physiological saline for fibrinogen estimations. All these solutions were stored at -20°C . in plastic tubes and used immediately after thawing.

Streptokinase.—The preparation produced by Lederle Laboratories (batch No. 2201-66) was used for plasminogen assays. It was diluted to 2,000 units/ml. in phosphate buffer and stored in plastic tubes at -20°C .

Urokinase.—The standard reference preparation (2,400 Plough units) produced by Leo Pharmaceuticals, Denmark (batch No. 63062) was used. Solutions of 3 units/ml. in tris buffer were prepared and stored at -20°C . in plastic tubes.

Glassware.—All glassware was siliconized by means of a 3% solution of I.C.I. M550 silicone in trichlorethylene.

* From the South-east Scotland Regional Blood Transfusion Research Laboratories, Royal Infirmary, Edinburgh.

Methods

Exercise Procedure.—All experiments were carried out during the morning, after a light breakfast, in a procedure-room at 19–20°C. Subjects abstained from smoking and excessive exercise on the morning prior to the experiment, and were required to rest, lying down, for 30 minutes before the initial venepuncture. At the end of the rest period each subject walked at 3.4 m.p.h. on a treadmill at 5 degrees elevation for a period of eight minutes. They were required to adjust their stride to 120 paces a minute. Pulse rates immediately before and after the exercise were recorded on an electrocardiograph.

Blood Sampling and Centrifugation.—From a vein in the cubital fossa 9 ml. of blood was withdrawn by clean venepuncture, with the minimum of venous occlusion, into a siliconized syringe. The blood was immediately transferred to a previously cooled centrifuge-tube, in melting ice, containing 1 ml. of 3.8% sodium citrate. The first sample remained in the melting ice until the second sample was withdrawn, immediately after the exercise, and then both were centrifuged at 3,400 r.p.m. at +4°C. for 20 minutes in a refrigerated centrifuge. The upper third of the plasma was transferred, by means of a siliconized pasteur pipette, into a pre-cooled plastic tube; euglobulin precipitation was performed immediately.

Euglobulin Lysis Time.—1 ml. of plasma was transferred to a siliconized centrifuge-tube in melting ice, containing 19 ml.

of distilled water and 0.18 ml. of 1% acetic acid. The pH was finally adjusted to 6.0, on a Beckman Zeromatic pH meter, 0.25% acetic acid being used. Precipitation time was 10 minutes from the addition of the plasma and was done in melting ice. The euglobulin suspensions were then centrifuged at 3,400 r.p.m. for 20 minutes at +4°C. The supernatant was discarded, the inside of the centrifuge tube wiped dry with a tissue, and the precipitate resuspended in 1 ml. of barbiturate buffer pH 7.4. 0.24 ml. of this euglobulin solution was transferred, in triplicate, to 3 by $\frac{3}{8}$ in. (7.5 by 1-cm.) siliconized test-tubes and 0.24 ml. of thrombin solution (5 units/ml. in barbiturate buffer pH 7.4) added immediately. The test-tubes were placed in a water-bath at 37°C. and the time taken from the addition of thrombin to complete lysis was recorded as the euglobulin lysis time.

Inhibitor Assay.—Inhibitor assays were based on the method of Blix (1964). Human fibrin plates were prepared by a modification of the method of Astrup and Müllertz (1952). 10 ml. of 0.15 g./100 ml. human fibrinogen in this buffer were pipetted into a plastic Petri dish, internal diameter 8.8 cm., and before clotting with 0.2 ml. of thrombin solution (50 units/ml. in tris buffer) on a level table, 1 ml. of euglobulin solution diluted in saline was added and thoroughly mixed. A series of four plates were used containing dilutions of 1/10, 1/25, and 1/50 and a control with 1 ml. of saline. Thence, 0.03-ml. drops of urokinase (3.0 units/ml. in tris buffer) were placed on to the

TABLE I.—Euglobulin Lysis Time Before and After Moderate Exercise in Male and Female Subjects Aged 18 to 30 Years

Subject No.	Males			Subject No.	Females		
	Euglobulin Lysis Time				Euglobulin Lysis Time		
	Before	After	Increase (%)		Before	After	Increase (%)
M 1	140 660 500	71 332 257	49 50 49 } 49	F 1	156 228 198	71 100 95	54 34 56 52 } 54
M 2	240 304	110 136	54 55 } 55	F 2	112 113 *99 97	70 75 62 61	38 34 37 37 } 37
M 3	195 105 135 77 83 148	120 58 80 45 51 92	48 45 40 42 39 38 } 43	F 3	115 88 177 *140	55 45 96 74	50 49 46 47 } 48
M 4	620 84 270 318 210	440 60 200 213 156	29 29 26 33 26 } 29	F 4	117 425 120	49 117 45	58 73 63 } 65
M 5	61 75 57 65 81	35 42 35 45 50	43 44 39 31 38 } 37	F 5	160 200	83 100	48 50 } 49
M 6	115 146	70 96	39 34 } 37	F 6	222 135 204 *192 193 143	97 71 90 95 97 70	56 47 56 51 50 51 } 52
M 7	105 131 77 76	60 78 47 50	43 41 39 34 } 39	F 7	102 141 90	48 65 45	53 54 50 } 52
M 8	550 211 745	440 172 505	20 19 32 } 24	F 8	132 370 300	53 134 100	60 64 67 } 64
M 9	143 150 150	60 65 62	58 57 59 } 58	F 9	132 *135 117 95	57 62 50 45	57 54 47 53 } 53
M 10	105 95 103	63 59 60	40 38 42 } 40	F 10	84 77 80	43 42 41	49 45 49 } 48
M 11	255 315 262	124 153 129	51 51 51 } 51	F 11	123 131 *132 120	72 75 74 75	42 43 44 38 } 42

* Results during menstruation.

TABLE I—continued

Subject No.	Males			Subject No.	Females		
	Euglobulin Lysis Time				Euglobulin Lysis Time		
	Before	After	Increase (%)		Before	After	Increase (%)
M 12	120 159 272 151 245 132	95 116 192 106 185 98	21 27 29 30 24 26	F 12	132 *135 145 142	62 65 71 62	53 52 51 49
M 13	494 720 274	211 370 137	57 48 50	F 13	180 306 250 148	92 142 117 71	49 54 53 52
M 14	100 113 110	54 56 52	46 50 53	F 14	595 185 90	380 110 53	36 41 41
M 15	112 223 180	52 104 80	54 53 56	F 15	105 110 100 *105	45 55 50 55	57 50 50 48
M 16	257 120 140	143 80 90	44 33 36	F 16	115 138 171	95 81 101	48 41 41
M 17	72 108 200 320	65 86 184 310	10 20 8 3	F 17	150 198 *178 178	76 93 87 95	49 51 45 41
M 18	189 270	99 137	48 49	F 18	166 176 162	85 104 95	49 41 42
M 19	65 84 94	51 56 64	22 33 32	F 19	176 202 200	103 124 120	42 39 40
M 20	250 230	160 150	36 35	F 20	121 131 117	68 73 65	43 44 44
M 21	116 108 110	87 82 85	25 24 23	F 21	68 80 *82 89	30 33 32 39	56 59 56 54
M 22	120 500	75 300	38 40	F 22	90 105 112	45 53 58	50 50 49
M 23	174 135 100	89 77 60	49 43 40	F 23	115 107	60 60	48 44
M 24	539 269	324 162	40 40	F 24	99 96 110	52 56 61	47 42 45
M 25	107 76 95	63 45 60	42 41 37	F 25	118 120	73 74	38 38

fibrin film in triplicate 20 minutes after clotting. The plates were incubated at 37°C. for 24 hours and the product of the perpendicular diameters taken as a measure of fibrinolytic activity.

Fibrinogen Assay.—The method of Ratnoff and Menzie (1951), as modified by Alkjaersig (1960), was used.

Plasminogen Assay.—The caseinolytic assay of Remmert and Cohen (1949), as modified by Alkjaersig *et al.* (1959), was used.

Results

Resting Levels of Euglobulin Lysis Time.—Table I shows the results in detail of all experiments. The resting level of plasminogen activator, as measured by the euglobulin lysis time, varied from subject to subject and from day to day in the same subject. This variation could not be correlated with the euglobulin fibrinogen and plasminogen on the 34 occasions they were assayed (Fig. 1). No urokinase inhibitor was demonstrated in the euglobulin solutions. The females had a lower euglobulin lysis time than the men, which was highly significant ($P<0.001$). There were no significant changes related to the phases during the menstrual cycle in the nine females studied.

FIG. 1.—Euglobulin plasminogen and fibrinogen plotted against the euglobulin lysis time.

Fibrinolytic Response to Moderate Exercise.—If A and B represent the resting and post-exercise euglobulin lysis times, respectively, then the percentage increase following exercise was calculated as $A - B/A \times 100$. The results of this calculation are shown in Table I for each experiment, and also the mean percentage response for each individual. The results indicated that, for any one subject, the fibrinolytic response was reproducible (correlation coefficient (r)=0.9929 and $P<0.001$). Furthermore, there was a highly significant individual variation in response (analysis of variance showed $F=36.7$, which was significant at the 1% level).

Table II shows the frequency distribution of the percentage response in all the subjects and that the females produced a

TABLE II.—Frequency Distribution of Percentage Response to Moderate Exercise

	Percentage Response					
	11-20	21-30	31-40	41-50	51-60	61-70
Males ..	1	5	9	5	5	0
Females ..	0	0	4	11	8	2
Total ..	1	5	13	16	13	2

significantly greater fibrinolytic response than the males ($P<0.01$). The individual variation in fibrinolytic response did not correlate with the pulse rate increase following exercise in the 22 subjects studied (Fig. 2). There was, however, a highly significant greater mean pulse-rate response in the female subjects (males 70 min., females 84 min., $P<0.001$). There appeared to be no significant changes in the fibrinolytic response to moderate exercise throughout a menstrual cycle.

FIG. 2.—Percentage increase in euglobulin lysis time plotted against increase in heart rate following moderate exercise.

Discussion

We have confirmed the findings of Blix (1961) that, even under carefully standardized assay procedures, the resting euglobulin lysis time varied from subject to subject and from day to day in the same subject. Despite the criticism of substrate variability, the euglobulin lysis time has been shown to be a good measure of plasminogen activator (Sawyer *et al.*, 1960; Iatridis and Ferguson, 1963; Fletcher *et al.*, 1964). We were unable to attribute the daily fluctuations in the euglobulin lysis time to the changes in euglobulin fibrinogen and plasminogen, nor was there evidence of a urokinase inhibitor in those euglobulin fractions giving a long lysis time. Although this problem is under investigation in this laboratory, we feel there is, as yet, insufficient evidence to exclude the possibility that the daily resting level of circulating plasminogen activator may vary in any one individual. Furthermore, it would appear, as suggested by Fearnley (1961), using the dilute blood-clot-assay technique, that this daily fluctuation is more pronounced in some individuals than in others.

The finding of a significant sex difference in the resting euglobulin lysis time is contrary to the observations of Beller *et al.* (1964) and Brakman *et al.* (1966). We are not able to explain this apparent discrepancy, but it may be relevant that previous conclusions have been reached, in the main, from single observations. We have confirmed, however, that the daily fluctuations in the resting euglobulin lysis time do not appear to be related to the menstrual cycle.

Despite this daily fluctuation, the level following a standard exercise procedure, in the same subject, appeared to be related in a constant way. Thus the fibrinolytic response (which we have termed "fibrinolytic reactivity") to a fixed moderate exercise procedure, expressed as a percentage of the pre-exercise level, in normal young subjects, is a reproducible phenomenon. There seems to be individual variation and there exists a small but definite group of poor responders. Of no less interest was the finding that women of the same age-group seem to have a greater fibrinolytic reactivity than men, and that in the group studied no female poor responders were discovered. There appeared to be no significant change in fibrinolytic reactivity during the menstrual cycle.

It is possible that the variation in fibrinolytic response may simply mirror the individual variation in stress to a standard exercise procedure. If pulse-rate response is a measure of the exercise stress, then the absence of a correlation, within each

sex group, would not confirm this view. When the two sex groups are compared, however, the position is less clear. The females showed a significantly higher pulse response than the males. This finding is in agreement with the work of Åstrand (1952), who suggested that the cause might be a stronger distaste in women for physical exertion, or that men may be more efficient working machines.

Severe exercise has been shown to increase body temperature (Holmgren and McIlroy, 1964) and severe heat stress increases plasma fibrinolytic activity (Bedrak *et al.*, 1963). Although at present we have no data which might elucidate this possible explanation of our results, we feel it unlikely that the moderate exercise procedure used was sufficient to produce significant changes in core temperature, which in turn would cause an increased plasma fibrinolysis.

We have been unable to explain our group of poor responders on the basis of physical fitness (Biggs *et al.*, 1947). Four of our volunteers were highly trained athletes and their mean response ranged from 24% to 54%. Iatridis and Ferguson (1963) demonstrated the generation of a fibrinolytic inhibitor following exercise in one of their poor responders. We have been unable to detect an increase in urokinase inhibitor content of our post-exercise euglobulin solutions, or in any euglobulin fractions precipitated at pH 6.

The significance of the fibrinolytic reactivity to exercise remains, as yet, unknown. We postulate that it may represent, in part, the ability of the individual to generate circulating plasminogen activator to stress. Exercise has also been shown to increase the coagulability of the blood (Vuori, 1950; Bond *et al.*, 1961; Iatridis and Ferguson, 1963; Burt *et al.*, 1964; von Kaulla and von Kaulla, 1964). Thus, on the basis of a dynamic equilibrium between coagulation and fibrinolysis, an increase in fibrinolysis would be anticipated. Iatridis and Ferguson (1963), however, observed that 11 of their 59 subjects failed to increase their circulating plasminogen activator following strenuous exercise despite an apparent increase in coagulability. Burt *et al.* (1964), in a study of coagulation and fibrinolysis following strenuous exercise, concluded that the mean changes were in favour of fibrinolysis. Examination of their results in more detail, however, shows that two of their 44 subjects gave a poor fibrinolytic response, whereas the coagulation changes in these subjects were similar to those in some of the subjects giving a marked fibrinolytic response.

Hypercoagulability and increased fibrinolysis have also been demonstrated during anxiety (Ogston *et al.*, 1962; Patsch, 1963). We postulate, therefore, that the possibility now arises that persons with a poor fibrinolytic reactivity may be subject to transitory episodes of coagulation-fibrinolysis disequilibrium during their day-to-day living. The disequilibrium might arise from either an exaggerated increase in coagulation associated with a normal increase in fibrinolysis, or vice versa. In the light of Astrup's hypothesis these persons may be at risk to atherosclerosis and/or thrombosis.

Evidence supporting this view is fragmentary. Cirrhotic patients have a low incidence of myocardial infarction (Grant *et al.*, 1959; Howell and Manion, 1960), and it has been shown that they may possess exaggerated fibrinolytic reactivity (Weiner, 1963; Fletcher *et al.*, 1964) as well as a general tendency to hypocoagulation (Ollendorff *et al.*, 1966). von Kaulla and von Kaulla (1964) have provided suggestive evidence that patients with a proved history of myocardial infarction may show an exaggerated hypercoagulability after exercise.

There is reason to believe that atherosclerosis may be prevalent in young males (Thomas, 1957; Holman *et al.*, 1958) and that women, during the reproductive period of their lives, are relatively immune (Thomas, 1957; Strong and McGill, 1962). Our findings of a small group of apparently normal young men with poor fibrinolytic reactivity to moderate exercise, and that women of the same age-group have a greater fibrinolytic reactivity, may therefore prove to be of some interest.

We believe that the study of coagulation and fibrinolysis, simultaneously, before and after exercise may prove to be a more relevant focusing-point for observing potential states of coagulation-fibrinolysis disequilibrium than a measurement of these values in the resting state, as has been the practice in the past (Hume, 1958; Lackner and Merskey, 1960; Nestel, 1960; Ogston, 1962; Katz *et al.*, 1963; Naimi *et al.*, 1963; MacKay and Hume, 1964; Chakrabarti *et al.*, 1966).

Summary

The euglobulin lysis time before and after moderate exercise has been studied in 25 male and 25 female normal subjects aged 18 to 30 years. The resting euglobulin lysis time varied from subject to subject and from day to day in the same subject. A highly significant lower level was found in the females. There was no correlation in the resting levels of euglobulin lysis time with the menstrual cycle.

The fibrinolytic reactivity to moderate exercise was reproducible in one individual, but there was a significant difference in reactivity between individuals, which revealed the presence of a group of consistently poor reactors. The fibrinolytic reactivity in women of the same age-group was significantly greater than that in men, but there appeared to be no changes coincident with the phases of the menstrual cycle.

The possible significance of these findings is discussed in the light of Astrup's hypothesis of the aetiology of atherosclerosis and/or thrombosis.

I wish to thank the many volunteers; Mr. A. G. E. Allan for invaluable technical assistance; Dr. R. A. Cumming, Director of the South-East Scotland Regional Blood Transfusion Centre, for providing the laboratory facilities; and Professor K. W. Donald, university department of medicine, for the generous provision of treadmill facilities. This research programme has been supported by a grant from the Scottish Hospital Endowments Research Trust.

REFERENCES

- Alkjaersig, N. (1960). *Proceedings of the Conference on Thrombolytic Agents, 8-9 April 1960*, edited by H. R. Roberts and J. D. Geraty, p. 136. Haematology Study Section (U.S.) Public Health Service.
- Fletcher, A. P., and Sherry, S. (1959). *J. clin. Invest.*, **38**, 1086.
- Åstrand, P.-O. (1952). *Experimental Studies of Working Capacities in Relation to Sex and Age*. Munksgaard, Copenhagen.
- Astrup, T. (1956). *Lancet*, **2**, 565.
- and Müllertz, S. (1952). *Arch. Biochem.*, **40**, 346.
- Bedrak, E., Beer, G., and Furman, K. I. (1963). *Israel J. exp. Med.*, **11**, 1.
- Beller, F. K., Goebelsmann, U., Douglas, G. W., and Johnson, A. (1964). *Obstet. and Gynec.*, **23**, 12.
- Biggs, R., Macfarlane, R. G., and Pilling, J. (1947). *Lancet*, **1**, 402.
- Billimoria, J. D., Drysdale, J., James, D. C. O., and MacLagan, N. F. (1959). *Ibid.*, **2**, 471.
- Blix, S. (1961). *Scand. J. clin. Lab. Invest.*, **13**, Suppl. No. 58, p. 3.
- (1964). *Ibid.*, **16**, 403.
- Blombäck, B., and Blombäck, M. (1957). *Ark. Kemi*, **10**, 415.
- Bond, T. P., Celander, D. R., and Guest, M. M. (1961). *Fed. Proc.*, **20**, 56.
- Brakman, P., Albrechtsen, O. K., and Astrup, T. (1966). *Brit. J. Haemat.*, **12**, 74.
- Burt, J. J., Blyth, C. S., and Rierston, H. A. (1964). *J. Sport. Med. (Torino)*, **4**, 213.
- Chakrabarti, R., Fearnley, G. R., Hocking, E. D., Delitheos, A., and Clark, G. M. (1966). *Lancet*, **1**, 573.
- Fearnley, G. R. (1961). *Ibid.*, **1**, 506.
- and Lackner, R. (1955). *Brit. J. Haemat.*, **1**, 189.
- Fletcher, A. P., Biederman, O., Moore, D., Alkjaersig, N., and Sherry, S. (1964). *J. clin. Invest.*, **43**, 681.
- Grant, W. C., Wasserman, F., Rodensky, P. L., and Thomson, R. V. (1959). *Ann. intern. Med.*, **51**, 774.
- Holman, R. L., McGill, H. C., Strong, J. P., and Geer, J. C. (1958). *Amer. J. Path.*, **34**, 209.
- Holmgren, A., and McIlroy, M. B. (1964). *J. appl. Physiol.*, **19**, 243.
- Howell, W. L., and Manion, W. C. (1960). *Amer. Heart J.*, **60**, 341.
- Hume, R. (1958). *Brit. Heart J.*, **20**, 15.
- Iatridis, S. G., and Ferguson, J. H. (1963). *J. appl. Physiol.*, **18**, 337.
- Jang, E., Fletcher, B. T., and Bickford, A. F. (1964). *Clin. Sci.*, **27**, 9.
- Katz, A. M., McDonald, L., Davies, B., and Edgill, M. (1963). *Lancet*, **1**, 801.
- von Kaulla, K. N., and von Kaulla, E. (1964). *Circulat. Res.*, **14**, 436.
- Lackner, H., and Merskey, C. (1960). *Brit. J. Haemat.*, **6**, 402.
- MacKay, N., and Hume, R. (1964). *Scot. med. J.*, **9**, 359.
- Naimi, S., Goldstein, R., and Proger, S. (1963). *Circulation*, **27**, 904.

- Nestel, P. J. (1960). *Aust. Ann. Med.*, **9**, 234.
 Ogston, D. (1962). *Brit. med. J.*, **1**, 1242.
 — and Fullerton, H. W. (1961). *Lancet*, **2**, 730.
 — and McAndrew, G. M. (1964). *Ibid.*, **2**, 1205.
 — McDonald, G. A., and Fullerton, H. W. (1962). *Ibid.*, **2**, 521.
 Ollendorff, P., Rasmussen, J., and Astrup, T. (1966). *Acta med. scand.*, **179**, 101.
 Owren, P. A. (1947). *Ibid.*, Suppl. No. 194.
 Patsch, J. (1963). *Wien. med. Wschr.*, **113**, 537.
 Ratnoff, O. D., and Menzie, C. (1951). *J. Lab. clin. Med.*, **37**, 316.

- Remmert, L. F., and Cohen, P. P. (1949). *J. biol. Chem.*, **181**, 431.
 Sawyer, W. D., Fletcher, A. P., Alkjaersig, N., and Sherry, S. (1960). *J. clin. Invest.*, **39**, 426.
 Sherry, S., Lindemeyer, R. I., Fletcher, A. P., and Alkjaersig, N. (1959). *Ibid.*, **38**, 810.
 Strong, J. P., and McGill, H. C. (1966). *Amer. J. Path.*, **40**, 37.
 Thomas, W. A. (1957). *Nutr. Rev.*, **15**, 97.
 Truelove, S. C. (1951). *Clin. Sci.*, **10**, 229.
 Vuori (1950). *Acta med. scand.*, **236**, 296.
 Weiner, M. (1963). *Amer. J. med. Sci.*, **246**, 294.

Medical Memoranda

Liver Damage and Impaired Glucose Tolerance after Paracetamol Overdosage

Brit. med. J., 1966, **2**, 506–507

Paracetamol is a widely used and comparatively safe antipyretic analgesic (*Brit. med. J.*, 1965; *Drug and Therapeutics Bulletin*, 1966). In view of its increasing clinical use, the following case history is of interest.

CASE HISTORY

A 54-year-old man weighing 7 st. 10 lb. (49 kg.) was admitted to the casualty ward at Woolmanhill, Aberdeen, on 11 September 1965, within two hours of consuming a bottle of beer and a number of paracetamol tablets, estimated at 70 by his wife. He had been taking the drug over a period of two years for low back pain of undetermined origin. There was nothing else of note in his past medical history, and, in particular, no history of liver disease or alcoholism. His mother was known to have had diabetes.

On admission he was drowsy, but no abnormal physical signs were elicited. The pulse rate was 78/min. and the blood-pressure 100/70 mm. Hg; the extremities were warm. The stomach was washed out, and the aspirate was reported to contain a "small amount of paracetamol." The serum concentration of paracetamol on admission was 76 mg./100 ml.

As the patient was cooperative, treatment was started with forced oral fluids. A urine sample obtained three hours after admission contained 2% glucose, but was otherwise normal. Over the next 12 hours the glycosuria continued, and as his general condition was deteriorating he was transferred to Woodend General Hospital on 12 September. On arrival he was lethargic but aggressive when disturbed, was incontinent of urine and faeces, and complained of blindness. He lay with his eyes deviated to the right, and horizontal nystagmus was present. From lack of cooperation full assessment of the nature and extent of the visual defect was not possible. No other abnormalities were found on physical examination. The pulse rate was now 110/minute and the blood-pressure 150/100 mm. Hg.

Investigations on 12 September showed: urine—glucose 1%, no acetone, bile, or urobilinogen; serum urea 20 mg./100 ml., blood sugar 146 mg./100 ml. (glucose oxidase method); haemoglobin 13.7 g./100 ml., W.B.C. 8,200/c.mm., and E.S.R. 3 mm./hour (Westergren).

On 13 September an oral glucose-tolerance test with 50 g. of glucose was abnormal, with a fasting blood-sugar level of 106 mg./100 ml., rising to 276 mg./100 ml. at one hour and falling to 184 mg./100 ml. at two hours (see Chart, curve 1). A 2,000-calorie diet containing 200 g. of carbohydrate was therefore started on 14 September together with 100 mg. of chlorpropamide daily. With no other treatment his general condition improved, there was no further glycosuria, and his vision returned to normal.

On 17 September he was noticed to be icteric, and although the liver was not enlarged clinically, he complained of upper abdominal pain.

Investigations showed:—urine: bilirubin ++, urobilinogen ++, no glucose or acetone; serum: bilirubin 4.4 mg./100 ml., Van den Bergh +, glutamic oxaloacetic transaminase (S.G.O.T.) 216 units, glutamic pyruvic transaminase (S.G.P.T.) 124 units, sodium 137, potassium 3.7, chloride 96, CO₂ 26.5 mEq/l., alkaline phosphatase 19 King-Armstrong units, proteins normal, urea 59 mg./100 ml., and fasting blood sugar 90 mg./100 ml.

Over the next four days the jaundice gradually faded and by 4 October the serum alkaline phosphatase was 11 units, the S.G.O.T. 46 units, and the S.P.G.T. 51 units. A repeat oral glucose-tolerance test showed considerable improvement (Chart, curve 2). The chlorpropamide was discontinued on 8 October, and a normal ward diet introduced on 16 October with no recurrence of the glycosuria. A third glucose-tolerance test on 28 October was normal (Chart, curve 3). Apart from persisting back pain which necessitated his transfer to an orthopaedic ward, his progress thereafter was uneventful.

COMMENT

The remarkable lack of reported side-effects of paracetamol suggests that it is comparatively safe when used in normal therapeutic doses. There is no doubt that this patient had taken and absorbed a large quantity of the drug. The high serum concentration of 76 mg./100 ml. is compatible with the estimated intake of 70 tablets (35 g.), as after ingestion of 2 g. of paracetamol, serum concentrations of up to 5 mg./100 ml. may be expected in normal subjects (Prescott and Conney, unpublished data).

Apart from the blindness (which we cannot explain), the presenting clinical features were unremarkable. It was not until six days after the paracetamol was taken that jaundice appeared; and had it not been for the initial finding of glycosuria the patient might well have been discharged home on the second or third day with the liver damage unrecognized. The results of the liver-function tests suggest hepatocellular damage rather